Joe Crowell

Joe has over 28 years of experience in the vaccine and biopharmaceutical industry with significant expertise in the design/build and operation of cGMP manufacturing facilities, technology transfer, process development, cGMP manufacturing, and supply chain in support of clinical stage and commercial programs. Prior to forming Crozet, Joe was with BioProtection Systems, the infectious disease subsidiary of NewLink Genetics Corp., with responsibilities for the development and cGMP manufacture of vaccines against infectious diseases with a major focus on the recombinant VSV-Ebola vaccine, supported by contracts with the Biological Advanced Research and Development Agency (BARDA) and the Defense Threat Reduction Agency (DTRA).

Prior to joining NewLink Joe was with GSK/Novartis Vaccines as the leader of a global development team with responsibilities for Bexsero®, a multi-component vaccine for the prevention of invasive meningococcal group B disease. These efforts included new registrations in countries around the world while simultaneously manufacturing and distributing this vaccine to meet growing market demand. This team also successfully managed the demanding challenge of submitting a Biologics License Application with the US FDA under a Breakthrough Therapy designation while utilizing the FDA’s Fast Track and Priority Review designations. Before Novartis, Mr. Crowell was with the Life Sciences Division of General Electric HealthCare / Xcellerex as the General Manager and V.P. of Operations, where he was responsible for the contract manufacturing and contract development business unit. These duties included CMC responsibilities for the vaccine and drug development efforts which brought a novel inactivated Yellow Fever vaccine from early research thru FDA IND submission and successful completion of Phase I clinical study.

Prior to joining GE/Xcellerex, Joe was the Site Head of Operations running a Lonza Biologics microbial fermentation facility where he was responsible for the commercial manufacturing of ONTAK®, under contract for Eisai Pharmaceuticals and also led the team responsible for the re-design, startup/validation, and commissioning of a biopharmaceutical manufacturing plant that contributed to the EMA and FDA licensure of ATryn® for GTC Biotherapeutics.

Prior to these assignments, Joe has held various positions of increasing responsibility in Technical Operations with a focus on biologics facility design/build and start-up and manufacturing operations including clinical manufacture leading to the commercialization of new biologics with companies such as Wyeth, Lonza, Becton Dickinson, Repligen Corp., and Abbott Biotech.

Joe received his BS degree from the University of Massachusetts, Dartmouth.